Advertisement

Trends in Treatment for Patients Hospitalized with Heart Failure with Preserved Ejection Fraction Before and After Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT)

      The TOPCAT trial investigated spironolactone vs placebo in patients with heart failure with preserved ejection fraction (HFpEF). Although the primary endpoint was not statistically significant, treatment with spironolactone did reduce heart failure hospitalizations compared with placebo. TOPCAT's impact on prescribing patterns in the United States is not well-characterized. We performed a retrospective analysis of discharge prescribing data in the Get With The Guidelines-Heart Failure Registry among patients with left ventricular ejection fraction ≥50% discharged between January 2009 and December 2016 to assess prescribing trends upon dissemination of TOPCAT results. Of 142,201 patients included in the study, 18,581 (13.1%) were prescribed mineralocorticoid receptor antagonists (MRAs) at discharge. Compared with those not prescribed MRAs, patients discharged on MRAs were generally younger (75 vs 78 years), and report white race (76.7% vs 72.0%), more likely to have had prior heart failure hospitalizations (75.5% vs 65.7%), lower brain natriuretic peptide levels (492 vs 545 pg/mL), but similar serum creatinine levels (1.2 vs 1.2 mg/dL) upon admission. MRA prescribing modestly increased over time (p <0.0001), without significant change in the overall trend of prescribing rate for MRAs after TOPCAT results were presented (p =0.17). In conclusion, our findings suggest that for patients with HFpEF, the use of MRAs at hospital discharge is low, with only modest increases over time and no discernible change in the rate of MRA use after the TOPCAT results were released. There remains an important need for more clinical trials to better establish the efficacy and safety of MRAs for the treatment of HFpEF.
      To read this article in full you will need to make a payment

      References

        • Benjamin EJ
        • Blaha MJ
        • Chiuve SE
        • Cushman M
        • Das SR
        • Deo R
        • de Ferranti SD
        • Floyd J
        • Fornage M
        • Gillespie C
        • Isasi CR
        • Jimenez MC
        • Jordan LC
        • Judd SE
        • Lackland D
        • Lichtman JH
        • Lisabeth L
        • Liu S
        • Longenecker CT
        • Mackey RH
        • Matsushita K
        • Mozaffarian D
        • Mussolino ME
        • Nasir K
        • Neumar RW
        • Palaniappan L
        • Pandey DK
        • Thiagarajan RR
        • Reeves MJ
        • Ritchey M
        • Rodriguez CJ
        • Roth GA
        • Rosamond WD
        • Sasson C
        • Towfighi A
        • Tsao CW
        • Turner MB
        • Virani SS
        • Voeks JH
        • Willey JZ
        • Wilkins JT
        • Wu JH
        • Alger HM
        • Wong SS
        • Muntner P
        • American Heart Association Statistics C and Stroke Statistics S
        Heart disease and stroke statistics-2017 update: a report from the American Heart Association.
        Circulation. 2017; 135: e146-e603
        • Owan TE
        • Hodge DO
        • Herges RM
        • Jacobsen SJ
        • Roger VL
        • Redfield MM
        Trends in prevalence and outcome of heart failure with preserved ejection fraction.
        N Engl J Med. 2006; 355: 251-2599
        • Yancy CW
        • Jessup M
        • Bozkurt B
        • Butler J
        • Casey Jr., DE
        • Colvin MM
        • Drazner MH
        • Filippatos GS
        • Fonarow GC
        • Givertz MM
        • Hollenberg SM
        • Lindenfeld J
        • Masoudi FA
        • McBride PE
        • Peterson PN
        • Stevenson LW
        • Westlake C
        2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the heart failure society of America.
        J Am Coll Cardiol. 2017; 70: 776-803
        • Pitt B
        • Pfeffer MA
        • Assmann SF
        • Boineau R
        • Anand IS
        • Claggett B
        • Clausell N
        • Desai AS
        • Diaz R
        • Fleg JL
        • Gordeev I
        • Harty B
        • Heitner JF
        • Kenwood CT
        • Lewis EF
        • O'Meara E
        • Probstfield JL
        • Shaburishvili T
        • Shah SJ
        • Solomon SD
        • Sweitzer NK
        • Yang S
        • McKinlay SM
        • Investigators T
        Spironolactone for heart failure with preserved ejection fraction.
        N Engl J Med. 2014; 370: 1383-1392
        • Yancy CW
        • Jessup M
        • Bozkurt B
        • Butler J
        • Casey Jr., DE
        • Colvin MM
        • Drazner MH
        • Filippatos GS
        • Fonarow GC
        • Givertz MM
        • Hollenberg SM
        • Lindenfeld J
        • Masoudi FA
        • McBride PE
        • Peterson PN
        • Stevenson LW
        • Westlake C
        2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Failure Society of America.
        J Card Fail. 2017; 23: 628-651
        • Writing Committee M
        • Yancy CW
        • Jessup M
        • Bozkurt B
        • Butler J
        • Casey Jr., DE
        • Drazner MH
        • Fonarow GC
        • Geraci SA
        • Horwich T
        • Januzzi JL
        • Johnson MR
        • Kasper EK
        • Levy WC
        • Masoudi FA
        • McBride PE
        • McMurray JJ
        • Mitchell JE
        • Peterson PN
        • Riegel B
        • Sam F
        • Stevenson LW
        • Tang WH
        • Tsai EJ
        • Wilkoff BL
        • American College of Cardiology Foundation/American Heart Association Task Force on Practice G
        2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.
        Circulation. 2013; 128: e240-e327
        • Albert NM
        • Yancy CW
        • Liang L
        • Zhao X
        • Hernandez AF
        • Peterson ED
        • Cannon CP
        • Fonarow GC
        Use of aldosterone antagonists in heart failure.
        JAMA. 2009; 302: 1658-1665
        • Pfeffer MA
        • Claggett B
        • Assmann SF
        • Boineau R
        • Anand IS
        • Clausell N
        • Desai AS
        • Diaz R
        • Fleg JL
        • Gordeev I
        • Heitner JF
        • Lewis EF
        • O'Meara E
        • Rouleau JL
        • Probstfield JL
        • Shaburishvili T
        • Shah SJ
        • Solomon SD
        • Sweitzer NK
        • McKinlay SM
        • Pitt B
        Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial.
        Circulation. 2015; 131: 34-42
        • Ponikowski P
        • Voors AA
        • Anker SD
        • Bueno H
        • Cleland JGF
        • Coats AJS
        • Falk V
        • Gonzalez-Juanatey JR
        • Harjola VP
        • Jankowska EA
        • Jessup M
        • Linde C
        • Nihoyannopoulos P
        • Parissis JT
        • Pieske B
        • Riley JP
        • Rosano GMC
        • Ruilope LM
        • Ruschitzka F
        • Rutten FH
        • van der Meer P
        • Group ESCSD
        2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.
        Eur Heart J. 2016; 37: 2129-2200
        • Cooper LB
        • Hammill BG
        • Peterson ED
        • Pitt B
        • Maciejewski ML
        • Curtis LH
        • Hernandez AF
        Characterization of mineralocorticoid receptor antagonist therapy initiation in high-risk patients with heart failure.
        Circ Cardiovasc Qual Outcomes. 2017; 10
      1. https://clinicaltrials.gov/ct2/show/NCT02901184?term=spirrit&cond=hfpef&draw=2&rank=1

      2. https://www.clinicaltrialsregister.eu/ctr-search/search?query=spirit+hf.

        • Lund LH
        • Oldgren J
        • James S
        Registry-based pragmatic trials in heart failure: current experience and future directions.
        Curr Heart Fail Rep. 2017; 14: 59-70